Revised US Approach For Parenteral Drug Leachables Could Prevent Regulatory Missteps
Executive Summary
Broad agreement across US FDA on modified PQRI recommendations could reduce approval delays over risk of chemicals leaching into parenteral drugs.
You may also be interested in...
2023 US FDA Drug Quality Guidance Expected To Include 20-Year CTD Update, Much More
A revision of the ICH Common Technical Document expected this year will set the global stage for eventual “structured” quality submissions. Meanwhile, the FDA plans to complete work on ICH impurities guidance and advanced manufacturing technology guidance.
Tales From CMC Reviews: Norliqva, Hydroxychloroquine, Glycopyrrolate And Sotyktu
Insights from US drug approval packages include how CMP Development navigated inspection challenges, how Novitium built a better scientific bridge, how Fresenius Kabi delivered on leachables & extractables, and how BMS addressed dissolution.
The Quality Lowdown: DSCSA, Recalls, Extractables & Leachables And Nitrosamines
The US FDA refines guidance on verification systems for suspect drug products and voluntary recalls, while industry groups issue guidance on extractables and leachables in parenteral drugs and the role of excipients in nitrosamine formation.